Claims
- 1. A compound of the formula ##STR26## where R is H, loweralkyl, halogen, cyano, loweralkanoyl, arylloweralkanoyl, aroyl, --CH(OH)r.sub.1, --C(OH)r.sub.1 r.sub.2, or --CH.sub.2 Or.sub.2 where r.sub.1 is H, loweralkyl, arylloweralkyl or aryl and r.sub.2 is loweralkyl; R.sub.1 is H, loweralkyl, arylloweralkyl, phenyl, nitrophenyl, cyanophenyl, trifluoromethylphenyl, aminophenyl, loweralkanoylaminophenyl, loweralkoxycarbonyl, arylloweralkoxycarbonyl, aryloxycarbonyl, loweralkylaminocarbonyl, arylloweralkylaminocarbonyl, arylaminocarbonyl, alkanoyl, arylloweralkanoyl, aroyl, alkenoyl or alkynoyl; and R.sub.2 is H, NO.sub.2, NH.sub.2, halogen, loweralkanoylamino, arylloweralkanoylamino, aroylamino or loweralkyl, or R.sub.2 as a whole is a combination of 2, 3 or 4 halogen atoms; or pharmaceutically acceptable acid addition salt thereof.
- 2. The compound as defined in claim 1 where R.sub.2 is H.
- 3. The compound as defined in claim 1 where R.sub.1 is H, loweralkyl or arylloweralkyl.
- 4. The compound as defined in claim 1 where R is H, loweralkyl, halogen, loweralkanoyl or --CH(OH)r.sub.1 where r.sub.1 is H or loweralkyl.
- 5. The compound as defined in claim 2 where R.sub.1 is H, loweralkyl or arylloweralkyl, and R is H, loweralkyl, halogen, loweralkanoyl or CH(OH)r.sub.1, r.sub.1 being H or loweralkyl.
- 6. The compound as defined in claim 1, which is N-(4-pyridinyl)-N-(1H-pyrrol-1-yl)-N'-methylurea.
- 7. The compound as defined in claim 1, which is N-(4-pyridinyl)-N-(1H-pyrrol-1-yl)carbamic acid ethyl ester.
- 8. The compound as defined in claim 1, which is N-(4-pyridinyl)-N-(1H-pyrrol-1-yl)-propanamide.
- 9. The compound as defined in claim 1, which is N-(4-pyridinyl)-N-(1H-pyrrol-1-yl)-linoleamide.
- 10. The compound as defined in claim 1, which is 3,4-dimethoxy-N-(4-pyridinyl)-N-(1-H-pyrrol-1-yl)phenylacetamide.
- 11. The compound as defined in claim 1, which is N-[3-[4-[[N-methyl-N-(1H-pyrrol-1-yl)]-amino]]pyridinyl]formamide.
- 12. The compound as defined in claim 1, which is N-(2-chloro-1H-pyrrol-1-yl)-N-(4-pyridinyl)carbamic acid ethyl ester.
- 13. The compound as defined in claim 1, which is N-(2-chloro-1H-pyrrol-1-yl)-N-(4-pyridinly)-3,4-dimethoxyphenylacetamide.
- 14. The compound as defined in claim 1, wherein R.sub.1 is methyl, which is .alpha.-methyl-1-[[N-(4-pyridinyl)-N-methyl]-amino]-1H-pyrrole-2-methanol.
- 15. The compound as defined in claim 1, which is N-(2-Chloro-1H-pyrrol-1-yl)-N-(4-pyridyl)-linoleamide 2-naphthalene sulfonate.
- 16. The compound as defined in claim 1, which is .alpha.-Ethyl-1[(N-(4-pyridinyl)-N-methyl]amino]-1H-pyrrole-2-methanol.
- 17. The compound as defined in claim 1, which is .alpha.Propyl-1-[[N-(4-pyridinyl)-N-methyl]amino]-1H-pyrrole-2-methanol.
- 18. The compound as defined in claim 1, which is 1-[[N-Methyl-N-(4-pyridinyl) amino]-1H-pyrrole-2-methanol.
- 19. The compound as defined in claim 1, which is N-(2-Formyl-1H-pyrrol-1-yl)-N-(2,3, 5,6-tetrachloro-4-pyridinyl)-carbamic acid ethyl ester.
- 20. A pharmaceutical composition which comprises an effective memory enhancing amount of a compound defined in claim 1 in a mixture with a pharmaceutically acceptable carrier or diluent.
- 21. A method of treating a patient in need of memory enhancement which comprises administering to the patient an effective memory enhancing amount of a compound defined in claim 1.
Parent Case Info
This is a division of prior application, Ser. No. 200,983, filed June 1, 1988, now U.S. Pat. No. 4,900,742, which is a division of prior application Ser. No. 804,430, filed Dec. 4, 1985, now U.S. Pat. No. 4,752,610.
Non-Patent Literature Citations (1)
Entry |
DeLarge et al., Eur. J. Med. Chem.-Chimica Therapeutical, Jul.-Aug. 1980, 15, 4, pp. 299-304. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
200983 |
Jun 1988 |
|
Parent |
804430 |
Dec 1985 |
|